

15 Earhart Drive, Suite 101, Amherst, NY 14221

REQUEST

Member Name:	Today's Date:	Date Needed:
Date of birth: Sex: Weight:	Prescriber:	Specialty:
Home Phone Number:	Phone Number:	Fax Number:
Home Address: City: State: Zip:	Address	City: State: Zip:
Payor: ☐ Independent Health ☐ Anne Arundel Health System ☐ Pharmacy Benefit Dimensions ☐ Medicaid ☐ Medicare ☐ Self-Funded ☐ Self-Funded ☐ Group Number:	Allergies: Additional Notes:	
DRUG SELECTION	ADDITIONAL CRITERIA	
□ REMICADE □ RENFLEXIS □ INFLECTRA □ AVSOLA Dose:	For treatment of Rheumatoid Arthritis: In addition to meeting the general crite be met.	
Frequency:	☐ Diagnosis of rheumatoid arthritis by	a rheumatologist
Expected duration of therapy:	☐ Authorization request must come fr	- :
Primary Diagnosis:	documented recommendation of a rhe Patient has failed to respond to a the	• ,
ICD 10 Code:	medication deemed a conventional ag as methotrexate, sulfasalazine, leflund	ent for rheumatoid arthritis, such
Please list all medications that patient has tried for the above diagnosis:	Please list:	
	For acute treatment and management In addition to meeting the general crite be met.	
General Authorization Criteria:	☐ Diagnosis of Crohn's disease or fist	tulizing Crohn's disease by a
☐ Place of administration has appropriate staff, equipment and	gastroenterologist ☐ Prior Authorization Request must co	ome from a gastroenterologist (or
medications to treat infusion-related reactions including epinephrine, diphenhydramine, corticosteroids, and oxygen	under the documented recommendati	•
Does patient have congestive heart failure? ☐ Yes ☐ No	☐ Patient has failed to respond to a th	
Patient's weight: Date:	medication deemed a conventional ag	jent for Crohn's disease, such as
Has the patient has been screened for latent TB infection? (i.e. tuberculin skin test or QuantiFERON®-TB Gold). □ Yes □ No	methotrexate, azathioprine, aminosali corticosteroids (including budesonide	
Please submit tuberculosis test result.	cyclosporine, and ciprofloxacin. Please list:	
 If this test is positive, then: Patient must be evaluated for latent tuberculosis before initiating infliximab therapy (latent tuberculosis should be treated before starting infliximab.); and 	For Pediatric Patients with Moderately Disease: In addition to meeting the general crite be met: □ Prior Authorization Request must on	to Severely Active Crohns eria, the following conditions must

Submission of yearly screening for latent TB, such as annual	under the documented recommendation of a gastroenterologist)	
TB skin testing results, is required for patients who live, travel, or work in situations where TB exposure is likely while on	☐ Patient is six years of age or older with a diagnosis of moderately to	
treatment or for those who have previously tested positive.	severely active Crohn's disease	
□ Patient has failed to respond to a three (3) month trial of one (1) medication deemed a conventional agent for Crohn's disease, such as methotrexate, azathioprine, aminosalicylates, 6-mercaptopurine, corticosteroids (including budesonide EC capsule), metronidazole, cyclosporine, and ciprofloxacin. Please list: For Ankylosing Spondylitis: In addition to meeting the general criteria, the following conditions must be met: □ The Authorization Request must come from a rheumatologist (or under the documented recommendation of a rheumatologist) □ Patient has failed to respond to a three (3) month trial of one (1) medication deemed a conventional agent for Ankylosing Spondylitis, such as NSAIDS, sulfasalazine, and Intraarticular	For Plaque Psoriasis: In addition to meeting the general criteria, the following conditions must be met: The Authorization Request must come from a dermatologist (or under the documented recommendation of a dermatologist) Duration of disease is greater than one year Chronic stable severe plaque psoriasis must cover at least 10% of total BSA; or Hands and/or feet of the patient are affected and severely interfere with the activities of daily living Patient has failed to respond to a three (3) month trial of one (1) medication deemed a conventional agent for psoriasis, such as methotrexate, tazarotene, topical corticosteroids, cyclosporine,	
corticosteroid therapy.	anthralin, tacrolimus, calcitriol, PUVA (phototherapy), and acitretin.	
Please list:	Please list:	
For Psoriatic Arthritis: In addition to meeting the general criteria, the following conditions must be met: The Authorization Request must come from a rheumatologist or dermatologist (or under the documented recommendation of a rheumatologist or dermatologist) Patient has failed to respond to a three (3) month trial of one (1) medication deemed a conventional agent for psoriatic arthritis, such as methotrexate, sulfasalazine, leflunomide, hydroxychloroquine, and NSAIDS Please list: Patient must have clinical features of psoriatic arthritis such as: involvement of the DIP joints, an asymmetric distribution of joint disease, spondylarthrosis, sausage digits, new bone formation on radiographs, cutaneous findings, and the characteristic nail manifestations of psoriatic arthritis (nail pitting, onycholysis and/or other lesions, which include leukonychia, red spots in the lunula, and nail plate crumbling). Please specify: Please specify:	For Moderate to Severely Active Ulcerative Colitis: In addition to meeting the general criteria, the following conditions must be met: Diagnosis of moderately to severely active ulcerative colitis by a gastroenterologist Prior Authorization Request must come from a gastroenterologist (or under the documented recommendation of a gastroenterologist); and Patient is 6 years of age or older Patient has failed to respond to a three (3) month trial of one (1) medication deemed a conventional agent for Ulcerative colitis, such as methotrexate, azathioprine, aminosalicylates, 6-mercaptopurine, corticosteroids (including budesonide EC capsule), and cyclosporine. Please list: For Re-Authorization: Coverage can be renewed based upon the following criteria: Patient continues to meet initiation criteria identified. Absence of unacceptable toxicity from the drug.	
	☐ Ongoing monitoring for TB as noted under criteria for authorization	
	☐ Clinical response or remission of disease is maintained with continued use	

©2021 Reliance Rx